Minmin Yang, PhD, Founder, Chairman
Dr. Yang received his PhD in organic synthesis from Auburn University, US in 2001, and did post-doctoral training at the same school from 2002 to 2004. Prior to founding PharmaBlock, he worked with increasing responsibilities from group leader to section head of medicinal chemistry at Roche Palo Alto and Roche China for 4 years. Dr. Yang has authored 80 publications, including 16 international patents.
Haijun Dong, PhD, MBA, Chief Executive Officer
Dr. Dong received his PhD from the University of Washington and MBA from China Europe International Business School. Prior experience includes: Senior Principal Scientist at Roche USA, Head of DMPK and Drug Safety at Roche China R&D Center, COO of Eli Lilly China R&D Center. Dr. Dong was a recipient of the “Leading Talents in Creativity, Innovation, and Entrepreneurship” selected globally by the National Nanjing High and New Tech Zone and Nanjing University of Technology, and the “Innovative and Entrepreneurial Talents” by the Jiangsu provincial government. Dr. Dong has authored over 30 publications, including about 10 Chinese and international patents.
Xihan Wu, PhD, Co-founder, Chief Technology Officer
Dr. Wu received his PhD in organic synthesis from Shanghai Institute of Materia Medica, CAS in 1999 and did postdoctoral training at University of Michigan from 1999 to 2002. Dr. Wu was a principle research investigator at Shanghai Institute of Materia Medica from 2002 to 2004. Prior to joining PharmaBlock, Dr. Wu worked in Roche R&D (China) for 6 years and was a Director of Medicinal Chemistry. Dr. Wu has authored over 50 publications, including 33 international patents.
Shuhai Zhao, PhD, Co-founder, Chief Scientific Officer
Dr. Zhao received his PhD in organic synthesis from The University of Paris-Sud, and did postdoctoral training at MIT. Prior to joining PharmaBlock in 2011, Dr. Zhao had 3 years of experience as a process chemist at Hoechst and over 15 years of experience as a medicinal chemist, project leader and group leader at Roche Palo Alto & Nutley, and as head of virology chemistry at Roche China. He led 5 project teams and discovered 7 clinical candidates, 3 of which have entered clinical trials and 2 were advanced into phase II. Dr. Zhao also contributed to the invention of FanaptTM. Dr. Zhao has authored over 70 publications, including 25 international patents.